CYTK:NGS-Cytokinetics Incorporated (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 71.41

Change

+0.26 (+0.37)%

Market Cap

USD 0.46B

Volume

2.48M

Analyst Target

USD 40.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
ARGX argenx NV ADR

N/A

USD 22.16B
BNTX BioNTech SE

N/A

USD 21.93B
GMAB Genmab AS

N/A

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 18.12B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing CYTK

BBC Virtus LifeSci Biotech Cl.. 1.55 % 0.79 %

N/A

USD 9.89M
CURE:AU ETFS S&P Biotech ETF 1.10 % 0.00 %

N/A

USD 0.04B
CBUSAS:SW Amundi S&P SmallCap 600 E.. 1.04 % 0.00 %

N/A

USD 0.12B
MWON:XETRA Amundi S&P SmallCap 600 E.. 1.04 % 0.00 %

N/A

USD 0.12B
USASUS:SW Amundi S&P SmallCap 600 E.. 1.04 % 0.00 %

N/A

USD 0.12B
AGED:SW iShares Ageing Population.. 0.87 % 0.00 %

N/A

N/A
ZSML-F:CA BMO S&P US Small Cap Inde.. 0.63 % 0.00 %

N/A

CAD 5.46M
ZSML-U:CA BMO S&P US Small Cap Inde.. 0.63 % 0.00 %

N/A

N/A
IDP6:SW iShares S&P SmallCap 600 .. 0.62 % 0.00 %

N/A

USD 1.71B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.92B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

USD 0.50B
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.50B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

USD 7.05B
2B77:XETRA iShares Ageing Population.. 0.00 % 0.00 %

N/A

USD 0.50B
IUS3:XETRA 0.00 % 0.00 %

N/A

N/A
ZSML:CA BMO S&P US Small Cap Inde.. 0.00 % 0.00 %

N/A

N/A
SMLE DBX ETF Trust - S&P Small.. 0.00 % 0.00 %

N/A

USD 1.27M
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.47% 30% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.47% 30% F 25% F
Trailing 12 Months  
Capital Gain 102.58% 86% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.58% 86% B+ 93% A
Trailing 5 Years  
Capital Gain 782.69% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 782.69% 97% N/A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 49.90% 85% B 91% A-
Dividend Return 49.90% 85% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.91% 52% F 31% F
Risk Adjusted Return 94.31% 100% F 97% N/A
Market Capitalization 0.46B 97% N/A 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 450.00 3% 3%
Price/Book Ratio 31.90 5% 3%
Price / Cash Flow Ratio -16.76 89% 85%
Price/Free Cash Flow Ratio -15.51 92% 87%
Management Effectiveness  
Return on Equity -572.15% 13% 5%
Return on Invested Capital -527.88% 4% 2%
Return on Assets -33.73% 43% 15%
Debt to Equity Ratio -157.22% 89% 94%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector